News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week’s ARASENS trial results should help pave the road.
The SEC announced charges against Usama Malik and his former live-in girlfriend Lauren S. Wood regarding an FDA decision during a trading black out.
Scientists from Cardiff University and the Arizona State University believe they have found the likely cause of blood clotting in some recipients of the Oxford-AstraZeneca COVID-19 vaccine.
It was recently announced that a low dose of the Pfizer-BioNTech vaccine is safe for kids ages 5 to 11.
IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.
Tune claims TEMPO can rapidly target and adjust the epigenomic machinery, controlling gene expression and dictating how the DNA will be molded.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The U.S. Centers for Disease Control and Prevention (CDC) reported that the Omicron variant of COVID-19 had been identified in California.
Four BMS employees have filed a lawsuit against BMS after claiming the company would not grant them a religious exemption and threatened their employment.
Novartis held an investor event to discuss their research programs, highlighting its partnership with Belgian pharma company UCB worth up to $1.5 billion.